STOCK TITAN
  1. Home
  2. CRXTW

CRXTW Stock Price, News & Analysis

CRXTW

Company Description

CRXTW (Nasdaq: CRXTW) is a publicly traded company.

CRXTW stock has declined 98.8% over the past year.

This page provides a comprehensive overview of CRXTW stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
0.00%
0.00
Last updated:
-98.77%
Performance 1 year
$0.0
Market Cap
0.0
Shares outstanding

CRXTW (CRXTW) stock. Over the past 12 months, the stock has lost 98.8%.

Latest News

View All
-26.28%

Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code

-41.69%

Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction

earnings
0.00%

Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)

-6.93%

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting

conferences
-12.72%

Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)

-11.96%

Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results

earnings

CRXTW has 10 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 8 with negative movement. Key topics include earnings, conferences. View all CRXTW news →

SEC Filings

View All

No SEC filings available for CRXTW.

Financial Highlights

—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months